Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:04:14 EST Sat 17 Jan 2026
Enter Symbol
or Name
USA
CA



Q:CRSP - CRISPR THERAPEUTICS AG - https://crisprtx.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CRSP - Q0.253.32·55.000.553.51-0.70-1.31,408.974,49719,84154.15  54.752  53.1078.48  30.0619:56:36Jan 1215 min RT 2¢

Recent Trades - Last 10 of 19841
Time ETExPriceChangeVolume
19:56:36Q53.43-0.78132
19:55:37Q53.48-0.735
19:47:35Q53.50-0.7120
19:45:15Q53.83-0.383
19:45:06Q53.83-0.381
19:41:20Q53.84-0.372
19:38:36Q53.50-0.715
19:30:10Q53.50-0.715
19:30:09Q53.50-0.71100
19:28:09Q53.50-0.7144

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-12 08:37U:CRSPNews ReleaseCRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones
2026-01-05 08:30U:CRSPNews ReleaseCRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-12-22 08:30U:CRSPNews ReleaseCRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112(TM)) in Autoimmune Diseases and Hematologic Malignancies
2025-12-16 12:00U:CRSPNews ReleaseFrom Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
2025-12-09 11:57U:CRSPNews ReleaseBeyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
2025-11-10 08:00U:CRSPNews ReleaseCRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
2025-11-08 09:56U:CRSPNews ReleaseCRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310(TM) Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering
2025-10-10 08:00U:CRSPNews ReleaseCRISPR Therapeutics Presents New Preclinical Data for CTX460(TM) Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase(TM) Editing Platform
2025-10-01 08:00U:CRSPNews ReleaseCRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
2025-09-22 08:30U:CRSPNews ReleaseCRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe
2025-09-09 16:00U:CRSPNews ReleaseCRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025
2025-09-02 08:00U:CRSPNews ReleaseCRISPR Therapeutics to Participate in Upcoming Investor Conferences
2025-08-04 16:15U:CRSPNews ReleaseCRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
2025-06-30 08:00U:CRSPNews ReleaseCRISPR Therapeutics Named to TIME's Most Influential Companies List of 2025
2025-06-26 07:00U:CRSPNews ReleaseCRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310(TM) Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline
2025-05-29 08:30U:CRSPNews ReleaseCRISPR Therapeutics to Participate in Upcoming Investor Conferences
2025-05-19 16:15U:CRSPNews ReleaseCRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies
2025-05-06 16:01U:CRSPNews ReleaseCRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310(TM) Targeting ANGPTL3
2025-04-03 08:00U:CRSPNews ReleaseCRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference